Organogenesis Holdings Inc. (ORGO)
NASDAQ: ORGO · Real-Time Price · USD
4.320
-0.180 (-4.00%)
Mar 31, 2025, 4:00 PM EDT - Market closed

Company Description

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States.

The company’s advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFU); Dermagraft, a dermal substitute grown from human dermal fibroblasts to treat DFUs; NuShield, a dehydrated placental allograft and surgical barrier to provide a protective barrier and ECM scaffold to support native healing; PuraPly Antimicrobial (AM) and PuraPly SX, which are antimicrobial barriers for the management of open wounds in surgical settings; and CYGNUS Dual, a dual-layered amniotic tissue graft used to treat chronic and acute wounds.

It also provides PuraPly MZ, a micronized version of PuraPly for the management of open wounds in surgical settings; FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; TransCyte, a bioengineered tissue scaffold that promotes burn healing; and PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications.

In addition, the company develops ReNu, a cryopreserved suspension, which is in Phase 3 trial, for the management of symptoms associated with knee osteoarthritis; and placental products.

It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices through direct sales representatives and independent agencies.

Organogenesis Holdings Inc. is headquartered in Canton, Massachusetts.

Organogenesis Holdings Inc.
Organogenesis Holdings logo
Country United States
Founded 1985
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 869
CEO Gary Gillheeney

Contact Details

Address:
85 Dan Road
Canton, Massachusetts 02021
United States
Phone 781 575 0775
Website organogenesis.com

Stock Details

Ticker Symbol ORGO
Exchange NASDAQ
Stock Type Common Stock
Share Class Class A Shares
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001661181
CUSIP Number 68621F102
ISIN Number US68621F1021
SIC Code 2834

Key Executives

Name Position
Gary S. Gillheeney Sr. President, Chief Executive Officer, Chair of the Board
David C. Francisco Chief Financial Officer
Patrick Bilbo Chief Operating Officer
Lori H. Freedman B.A., Esq., J.D. Chief Administrative and Legal Officer
Brian Grow Chief Commercial Officer
William R. Kolb CPA Secretary
Robert Cavorsi Vice President of Strategy

Latest SEC Filings

Date Type Title
Mar 27, 2025 8-K Current Report
Mar 17, 2025 144 Filing
Feb 27, 2025 10-K Annual Report
Feb 27, 2025 8-K Current Report
Feb 11, 2025 SCHEDULE 13G/A Filing
Jan 13, 2025 SCHEDULE 13D/A Filing
Jan 3, 2025 SCHEDULE 13D/A Filing
Dec 23, 2024 424B3 Prospectus
Dec 20, 2024 EFFECT Notice of Effectiveness
Dec 20, 2024 UPLOAD Filing